164 results
8-K
EX-1.1
FATE
Fate Therapeutics Inc
20 Mar 24
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
5:32pm
to employee benefit plans, qualified stock option plans or other employee compensation plans, or pursuant to outstanding options, rights or warrants disclosed … efforts are underway with respect to Company employees.
(aa) ERISA and Employee Benefits Matters. To the knowledge of the Company, no “prohibited
424B5
FATE
Fate Therapeutics Inc
20 Mar 24
Prospectus supplement for primary offering
5:30pm
and also officers, and employee stock plans, in some instances; or
at or after the time the stockholder became interested, the business combination
8-K
EX-99.1
9q0r63 onlzy7lni9b
3 May 23
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
4:06pm